Please login to the form below

Not currently logged in
Email:
Password:

obinutuzumab

This page shows the latest obinutuzumab news and features for those working in and with pharma, biotech and healthcare.

Venclexta plus Gazyva approval adds to non-chemo options in CLL

Venclexta plus Gazyva approval adds to non-chemo options in CLL

Joins Imbruvica combo in front line use. Roche has gained FDA approval for Venclexta (venetoclax) in combination with Gazyva (obinutuzumab) in a new front line use in patients with previously untreated

Latest news

  • Roche files Venclexta plus Gazyva in CLL Roche files Venclexta plus Gazyva in CLL

    Chemo-free combo assessed via FDA's Real-Time review. Roche has filed Venclexta (venetoclax) in combination with Gazyva (obinutuzumab) with the FDA for a new front line use in patients

  • Imbruvica and Gazyvo approved in first non-chemo CLL use Imbruvica and Gazyvo approved in first non-chemo CLL use

    The approval is also good news for Roche and its drug Gazyvo (obinutuzumab) which the company is trying to prove as superior next-generation version of MabThera/Rituxan (rituximab) which is ... Imbruvica as a single agent – and now as a combination

  • Roche and AbbVie prepare to move Venclexta into first-line CLL Roche and AbbVie prepare to move Venclexta into first-line CLL

    Venclexta (venetoclax) given in combination with Roche’s anti-CD20 drug Gazyva/Gazyvaro (obinutuzumab) has been shown to extend progression-free survival (PFS) compared to Gazyva plus chlorambucil chemotherapy – already approved

  • AbbVie trial backs chemo-free Imbruvica combo regimen AbbVie trial backs chemo-free Imbruvica combo regimen

    The iLLUMINATE trial showed that oral BTK inhibitor Imbruvica (ibrutinib) plus anti-CD20 injection Gazyva (obinutuzumab) was more effective than Gazyva plus chemo (chlorambucil) in treatment-naïve, older patents (aged 65

  • NICE backs Roche’s Gazyvaro after initial rejection NICE backs Roche’s Gazyvaro after initial rejection

    Last September the cost-effectiveness watchdog turned down Gazyvaro (obinutuzumab) for use with chemotherapy in previously-untreated patients with advanced follicular lymphoma (FL) at elevated risk of relapse, saying the dug

More from news
Approximately 11 fully matching, plus 21 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

What are you doing, Dave?
Artificial Intelligence (AI) is invading all areas of healthcare. Is it our saviour or our nemesis?...
Fake News is Bad for your Health
Ill informed patients make poor health decisions...
Secrets of Pharma Advertising
If the goal of branding is to be different, why do so many Pharma brand ads look the same?...

Infographics